Graig Suvannavejh
Stock Analyst at Mizuho
(4.52)
# 263
Out of 5,154 analysts
175
Total ratings
54.55%
Success rate
20.99%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $19 → $20 | $20.07 | -0.35% | 12 | Mar 5, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $134.39 | +86.03% | 2 | Feb 25, 2026 | |
| INSM Insmed | Maintains: Outperform | $211 → $204 | $140.13 | +45.58% | 13 | Feb 24, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $5.30 | +88.68% | 1 | Feb 19, 2026 | |
| IMMX Immix Biopharma | Initiates: Outperform | $14 | $9.29 | +50.70% | 1 | Feb 9, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $15.47 | -67.68% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $42.82 | +26.11% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $173.30 | +11.94% | 2 | Dec 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $28.33 | +62.37% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $73.26 | +36.50% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $9.86 | +133.27% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $67.37 | -16.88% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $33.19 | +38.60% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $162.33 | +24.44% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.48 | +170.27% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.28 | +10,687.49% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $2.00 | +75.00% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.02 | +65.56% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.33 | +87.62% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $15.80 | -30.36% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $15.75 | +65.08% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $13.85 | -42.24% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.97 | +0.09% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.51 | +403.31% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $8.01 | +823.85% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.80 | -64.29% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $93.52 | -62.57% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $24.86 | -67.82% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $60.41 | -5.64% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $29.27 | -82.92% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $10.52 | +223.19% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $10.05 | +178.61% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $27.82 | +11.43% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $15.12 | +2,413.23% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.63 | +191.02% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $24.00 | +50.00% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $32.92 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $3.23 | +1,045.51% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $182.01 | -29.67% | 1 | Sep 14, 2020 |
Apellis Pharmaceuticals
Mar 5, 2026
Maintains: Neutral
Price Target: $19 → $20
Current: $20.07
Upside: -0.35%
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $134.39
Upside: +86.03%
Insmed
Feb 24, 2026
Maintains: Outperform
Price Target: $211 → $204
Current: $140.13
Upside: +45.58%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $5.30
Upside: +88.68%
Immix Biopharma
Feb 9, 2026
Initiates: Outperform
Price Target: $14
Current: $9.29
Upside: +50.70%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $15.47
Upside: -67.68%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $42.82
Upside: +26.11%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $173.30
Upside: +11.94%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $28.33
Upside: +62.37%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $73.26
Upside: +36.50%
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $9.86
Upside: +133.27%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $67.37
Upside: -16.88%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $33.19
Upside: +38.60%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $162.33
Upside: +24.44%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.48
Upside: +170.27%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.28
Upside: +10,687.49%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.00
Upside: +75.00%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.02
Upside: +65.56%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.33
Upside: +87.62%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $15.80
Upside: -30.36%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $15.75
Upside: +65.08%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $13.85
Upside: -42.24%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.97
Upside: +0.09%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.51
Upside: +403.31%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $8.01
Upside: +823.85%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.80
Upside: -64.29%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $93.52
Upside: -62.57%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $24.86
Upside: -67.82%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $60.41
Upside: -5.64%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $29.27
Upside: -82.92%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $10.52
Upside: +223.19%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $10.05
Upside: +178.61%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $27.82
Upside: +11.43%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $15.12
Upside: +2,413.23%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.63
Upside: +191.02%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $24.00
Upside: +50.00%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $32.92
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $3.23
Upside: +1,045.51%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $182.01
Upside: -29.67%